Hepatic arterial infusion chemotherapy combined with lenvatinib and PD‐1 inhibitors versus lenvatinib and PD‐1 inhibitors for HCC refractory to TACE
L Diao, C Wang, R You, B Leng, Z Yu… - Journal of …, 2024 - Wiley Online Library
Abstract Background and Aim The study aims to investigate the efficacy and safety of hepatic
arterial infusion chemotherapy (HAIC) combined with lenvatinib and immune checkpoint …
arterial infusion chemotherapy (HAIC) combined with lenvatinib and immune checkpoint …
[HTML][HTML] Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular …
LW Lin, K Ke, LY Yan, R Chen, JY Huang - Frontiers in Oncology, 2023 - frontiersin.org
Background The subsequent therapy for hepatocellular carcinoma (HCC) patients with
refractory to transarterial chemoembolization (TACE) is still controversial. This study was …
refractory to transarterial chemoembolization (TACE) is still controversial. This study was …
The Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy Combined with PD-(L) 1 Inhibitors and Molecular Targeted Therapies for the Treatment of …
HH Tang, MQ Zhang, ZC Zhang, C Fan… - Journal of …, 2023 - Taylor & Francis
Objective To investigate the efficacy and safety of hepatic arterial infusion chemotherapy
(HAIC) combined with PD-(L) 1 inhibitors and molecular targeted therapies (MTT) for …
(HAIC) combined with PD-(L) 1 inhibitors and molecular targeted therapies (MTT) for …
[HTML][HTML] Efficacy and safety of TACE combined with lenvatinib plus PD-1 inhibitors compared with TACE alone for unresectable hepatocellular carcinoma patients: a …
S Qu, X Zhang, Y Wu, Y Meng, H Pan, Q Fang… - Frontiers in …, 2022 - frontiersin.org
Purpose: To compare the efficacy and safety of the combination of transcatheter arterial
chemoembolization (TACE), Lenvatinib, and programmed cell death protein-1 (PD-1) …
chemoembolization (TACE), Lenvatinib, and programmed cell death protein-1 (PD-1) …
Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study
M Cai, W Huang, J Huang, W Shi, Y Guo… - Frontiers in …, 2022 - frontiersin.org
Purpose To investigate the efficacy and safety of transarterial chemoembolization (TACE)
combined with lenvatinib plus PD-1 inhibitor (TACE-LP) versus TACE combined with …
combined with lenvatinib plus PD-1 inhibitor (TACE-LP) versus TACE combined with …
[HTML][HTML] Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: a …
P Guo, X Pi, F Gao, Q Li, D Li, W Feng, W Cao - Frontiers in Oncology, 2022 - frontiersin.org
Purpose: We conducted a retrospective study to compare transarterial chemoembolization
(TACE) plus lenvatinib plus anti-programmed death-1 (PD-1) blockade with TACE plus …
(TACE) plus lenvatinib plus anti-programmed death-1 (PD-1) blockade with TACE plus …
[HTML][HTML] Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two …
B Sun, L Zhang, T Sun, Y Ren, Y Cao, W Zhang… - Frontiers in …, 2022 - frontiersin.org
Objectives To compare the safety and efficacy of lenvatinib (LEN) combined with
camrelizumab plus transcatheter arterial chemoembolization (TACE-LEN-C) and TACE …
camrelizumab plus transcatheter arterial chemoembolization (TACE-LEN-C) and TACE …
[HTML][HTML] Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable …
KP Ma, JX Fu, F Duan, MQ Wang - World Journal of …, 2024 - ncbi.nlm.nih.gov
BACKGROUND The efficacy and safety of transarterial chemoembolization (TACE)
combined with lenvatinib plus programmed cell death protein-1 (PD-1) for unresectable …
combined with lenvatinib plus programmed cell death protein-1 (PD-1) for unresectable …
Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein‐1 inhibitors: A promising treatment approach for high‐burden hepatocellular …
S Fu, Y Xu, Y Mao, M He, Z Chen, S Huang… - Cancer …, 2024 - Wiley Online Library
Background Hepatic arterial infusion chemotherapy (HAIC) has demonstrated remarkable
local therapeutic efficacy in treating patients with large unresectable hepatocellular …
local therapeutic efficacy in treating patients with large unresectable hepatocellular …
A retrospective study exploring the safety and efficacy of hepatic arterial infusion chemotherapy and sequential transarterial embolization combined with lenvatinib …
JH Zhong, ZS Chen, LN Qi, ZM Zhang, BD Xiang, L Ma - 2023 - ascopubs.org
e16219 Background: Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin,
leucovorin, and 5-fluorouracil (FOLFOX) and lenvatinib with or without immune checkpoint …
leucovorin, and 5-fluorouracil (FOLFOX) and lenvatinib with or without immune checkpoint …